EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exploring Quinazoline as a Scaffold for Developing Novel Therapeutics in Alzheimer’s Disease

Qais Abualassal iD, Zead Abudayeh iD, Ala' Sirhan iD, Abdulrahman Mkia iD

Molecules · 2025

DOI: 10.3390/molecules30030555 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2025. Verfasst von Qais Abualassal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Queen Alia International Airport Street, A…. Hauptthemen laut MEDLINE: Alzheimer Disease, Quinazolines, Neuroprotective Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quinazoline, a privileged scaffold in medicinal chemistry, offers promising potential in the synthesis of anti-Alzheimer’s disease (AD) drugs. This heterocyclic compound, characterized by its fused benzene and pyrimidine rings, enables the design of multifunctional agents targeting AD pathology. The drug-like aspects and pharmaceutical features of quinazoline derivatives have the potential to give rise to various therapeutic drugs. AD is a progressive neurodegenerative condition marked by memory decline, cognitive deterioration, and language disorders. Given its complexity and multifaceted nature, there is a pressing need to discover multi-target drugs to effectively address this debilitating disorder. A comprehensive literature review has demonstrated that quinazoline derivatives exhibit a wide range of therapeutic potential for AD. These compounds function as inhibitors of cholinesterases, β-amyloid aggregation, oxidative stress, and tau protein, among other protective effects. Here, we highlight the most significant and recent research on quinazoline-based anti-AD agents, aiming to support the development and discovery of novel treatments for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseQuinazolinesNeuroprotective AgentsHumansAmyloid beta-PeptidesCholinesterase InhibitorsAnimalstau ProteinsOxidative Stress

Stichwörter der Autor:innen

Alzheimer’s diseasebeta-amyloid hypothesischolinergic hypothesisdrug discoveryquinazoline

Substanzen

QuinazolinesAmyloid beta-PeptidesCholinesterase Inhibitorstau ProteinsNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Queen Alia International Airport Street, Amman 11622, Jordan.
  • Department of Pharmacy, Faculty of Pharmacy, Amman Arab University, Amman 11953, Jordan.
  • Department of Biotechnology, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan.

ORCID-Profile: Qais Abualassal, Zead Abudayeh, Ala' Sirhan, Abdulrahman Mkia

Zitieren

APA

Abualassal, Q., Abudayeh, Z., Sirhan, A., & Mkia, A. (2025). Exploring Quinazoline as a Scaffold for Developing Novel Therapeutics in Alzheimer’s Disease. Molecules. https://doi.org/10.3390/molecules30030555

Vancouver

Abualassal Q, Abudayeh Z, Sirhan A, Mkia A. Exploring Quinazoline as a Scaffold for Developing Novel Therapeutics in Alzheimer’s Disease. Molecules. 2025. doi:10.3390/molecules30030555

BibTeX
@article{Abualassal2025,
  author = {Abualassal, Qais and Abudayeh, Zead and Sirhan, Ala' and Mkia, Abdulrahman},
  title = {Exploring Quinazoline as a Scaffold for Developing Novel Therapeutics in Alzheimer’s Disease},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30030555}
}
Kostenlos starten →